The impact of reimbursement negotiations on cost and availability of new pharmaceuticals: evidence from an online experiment.

ABSTRACT: BACKGROUND:The necessity to measure and reward "value for money" of new pharmaceuticals has become central in health policy debates, as much as the requirement to assess the "willingness to pay" for an additional, quality-adjusted life year (QALY). There is a clear need to understand the capacity of "value-based" pricing policies to impact societal goals, like timely access to new treatments, sustainable health budgets, or incentivizing research to improve patient outcomes. Not only the pricing mechanics, but also the process of value assessment and price negotiation are subject to reform demands. This study assesses the impact of a negotiation situation for life-extending pharmaceuticals on societal outcomes. Of interest were general effects of the bargaining behaviour, as well as differe

SUBMITTER: Wettstein DJ 

PROVIDER: S-EPMC7243324 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature